Feature|Videos|March 19, 2026

What Does a Truly Ai-Native Patient Access Infrastructure Look Like in 2026?

Ankit Jain, CEO, Co-Founder, Infinitus, discusses how AI-native patient access infrastructure appears to be less about replacing care teams and more about eliminating the friction between diagnosis and therapy initiation.

In a conversation with Pharmaceutical Executive, Ankit Jain, CEO, Co-Founder, Infinitus discusses how Infinitus is reimagining patient access through AI, aiming to streamline the patient journey from diagnosis to therapy adherence. Jain notes how Infinitus focuses on reducing friction points like prior authorization and benefit verification, leveraging AI to handle repetitive tasks and empower care teams to provide empathetic care.

A transcript of Jain’s conversation with Pharmaceutical Executive can be found below.

Pharmaceutical Executive: What does a truly AI-native patient access infrastructure look like in 2026 and how far is the industry from actually getting there?
Ankit Jain: When we think about the patient journey at Infinitus, it starts a lot before even a prescription is written. It starts from when the patient is given a diagnosis. It's from the point when they realize that their life is about to change, from the moment when the anxiety comes in, all the way to them getting on therapy and staying on therapy.

Now the unfortunate truth is, of the people that get a diagnosis, a small percentage actually get on the appropriate therapies, and then an even smaller percentage stay on those therapies. Our job at Infinitus is to help the teams that deliver the care make sure it actually arrives. We want to make sure that every step of the way the friction that exists, whether it is patient education, whether it is access to information about what's coming next, whether it is overcoming barriers like prior authorization or benefit verification or just moving the train along, how can we use AI to complement our teams so we can actually deliver the care that our system has so diligently designed and developed.

All the billions of dollars that have gone into coming up with therapies, all the care teams that have been assembled, how can we make sure they can work together seamlessly to get the patient to be healthier and drive better health outcomes?

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.